天智航(688277) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥23,319,659.79, a decrease of 17.89% compared to the same period last year[5] - The net profit attributable to shareholders was -¥38,163,337.19, with a year-to-date loss of -¥82,341,843.73, indicating a significant decline in profitability[5] - The basic earnings per share for the quarter was -¥0.09, reflecting a 50% increase in losses compared to the same period last year[11] - Net profit for Q3 2022 was a loss of CNY 87,757,969.44, compared to a loss of CNY 64,196,247.39 in Q3 2021, indicating a worsening financial performance[20] - The net loss attributable to shareholders of the parent company for Q3 2022 was CNY 82,341,843.73, compared to a loss of CNY 63,764,563.64 in Q3 2021[21] - The comprehensive income total for Q3 2022 was a loss of CNY 86,961,665.96, compared to a loss of CNY 62,180,881.96 in Q3 2021[21] - Basic and diluted earnings per share for Q3 2022 were both CNY -0.20, compared to CNY -0.15 in Q3 2021[21] Research and Development - Research and development expenses totaled ¥28,693,662.73 for the quarter, representing a 23.75% increase year-on-year[6] - The ratio of R&D expenses to operating revenue was 123.04%, an increase of 41.39 percentage points compared to the previous year[6] - Research and development expenses for Q3 2022 were CNY 80,328,845.46, an increase of 15% from CNY 69,879,548.32 in Q3 2021, reflecting a focus on innovation[20] - The company experienced a 52.30% increase in net loss attributable to shareholders compared to the same period last year, primarily due to increased R&D expenses and decreased other income[10] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,210,246,612.90, down 5.38% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,210,246,612.90, a decrease from RMB 1,279,050,151.42 at the end of 2021, reflecting a decline of approximately 5.4%[15] - The total liabilities as of Q3 2022 amounted to CNY 229,640,842.06, up from CNY 211,482,714.62 in Q3 2021[20] - The total current liabilities decreased to RMB 108,878,839.06 from RMB 113,226,037.45, indicating a reduction of about 3.1%[16] - The total equity attributable to shareholders of the parent company decreased to CNY 925,401,691.42 from CNY 1,006,947,231.67 in the previous year[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥129,972,334.28, with significant fluctuations due to changes in cash receipts and payments[11] - The cash flow from operating activities for the first three quarters of 2022 was CNY 86,627,082.28, an increase from CNY 82,547,196.15 in the same period of 2021[24] - The net cash flow from operating activities was -129,972,334.28, compared to -82,650,277.44 in the previous year, indicating a decline in operational cash flow[25] - The total cash outflow from operating activities was 248,997,354.83, compared to 236,161,051.02 in the previous year, indicating increased operational expenses[25] - The cash and cash equivalents at the end of the period were 168,038,447.01, down from 416,628,498.93 year-over-year[26] Shareholder Information - The company reported a total of 16,440 common shareholders at the end of the reporting period[12] - The top shareholder, Zhang Songgen, holds 75,664,000 shares, representing 18.02% of the total shares[12] Inventory and Investments - The inventory increased to RMB 48,727,695.02 from RMB 37,944,429.67, representing an increase of about 28.5% year-over-year[15] - The long-term equity investments increased to RMB 24,833,837.00 from RMB 19,995,742.59, reflecting a growth of approximately 24.1%[16] - The company reported a total of RMB 76,504,550.48 in trading financial assets, down from RMB 120,628,447.13, a decrease of about 36.5%[15] - Cash inflow from recovering investments was 226,045,467.80, down from 428,670,218.84 year-over-year, indicating a decline in investment recovery[25] Operational Highlights - The company has performed over 30,000 surgeries using its orthopedic surgical robots as of the end of the reporting period, marking a significant increase from the previous year[14] - The company has successfully implemented multiple installations of its "purchase technology services" model by the end of the reporting period[14]